Korean Biotech Funding Hits $1.4 Billion as VCs Exit Pricey AI

South Korean biotech companies raised $1.4 billion, according to KED Global, as venture capital firms pull back from artificial intelligence deals they now consider overvalued.

The figure marks a sharp surge in funding for the country's life sciences sector. Venture investors who spent the past two years chasing AI startups have begun rotating capital into biotech, where they see more attractive entry prices and stronger fundamentals, KED Global reports.

The shift reflects a broader repricing in the AI segment. After aggressive bidding pushed valuations of Korean AI startups to levels investors increasingly view as unsustainable, fund managers are redirecting new commitments toward pharmaceutical and biotechnology companies with tangible pipelines and clearer paths to commercialization.

Biotech has absorbed the inflow. The $1.4 billion total represents one of the strongest funding periods on record for the sector in South Korea, per KED Global's reporting.

The rotation carries consequences for both industries. AI startups may face tougher fundraising conditions as their most aggressive backers turn elsewhere. Biotech founders, by contrast, gain leverage in negotiations and access to deeper pools of patient capital.

For Korean venture firms, the calculus is straightforward: capital deployed into biotech today buys more equity and more science than the same money spent in a crowded AI market. If the trend holds, South Korea's biotech sector could consolidate its position as a primary destination for the country's venture capital over the coming funding cycles.